Long-term Efficacy of Pramipexole in Anhedonic Depression

Inclusion Criteria: * Previous participation in RCT testing the short-term efficacy of pramipexole vs placebo (EudraCT# 2022-001563-26). * Study participants randomized to pramipexole in the RCT who wish to continue with their treatment can enrol in the study. * Study participants randomized to placebo in the RCT who continue to fulfil the inclusion criteria (and none of the exclusion criteria) after the RCT can enrol in the study. * The research subject has given informed consent to participate in the study. Additional inclusion criterion for patients receiving placebo during the RCT * Anhedonia symptoms: 3 or 4 points on ≥ 3 items of the Snaith-Hamilton Pleasure Scale (SHAPS-C). This has been adopted in previous studies as a definition of "clinically significant anhedonia". Exclusion Criteria: * Pregnancy, breastfeeding or planned pregnancy (if female). * High suicide risk according to the overall clinical assessment of the research physician. * Ongoing substance abuse (within 6 months). * Diagnosis of current psychosis. * Known diagnosis of Emotionally Unstable Personality Disorder. * Treatment under LPT. * History of impulse control disorder (including current binge-eating disorder) or a current ADHD diagnosis with hyperactivity. * Diagnosis of intellectual disability, dementia, or other circumstance that makes it difficult to understand the meaning of participating in the trial and give informed consent. * Diagnosis of renal failure or severe cardiovascular disease …